Advanced Filters
noise
Found 2,081 clinical trials
C Clinical Trials Contact

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

The purpose of this research study is to evaluate the outcomes of two standard of care group exercise regimens to increase muscle mass in women who have been treated with breast cancer.

20 - 89 years of age Female Phase N/A
N Nicole Simone, MD

Prospective Breast Cancer Biospecimen Collection

Tissue will be procured during a standard of care procedure the patient will already be scheduled to undergo. A one time blood draw will be performed at this time and an optional rectal swab for biome analysis may occur. Follow Up will only consist of chart review to determine date …

18 years of age All Phase N/A
S Sung Gwe Ahn, MD, PhD

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

20 - 50 years of age Female Phase 4
M Meiting Chen, Doctor

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer

18 years of age Female Phase 2
M Manuel Ruiz Borrego

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

The multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in Hormone Receptor (HR)-known/Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog …

18 years of age All Phase 2
R Reshma L Mahtani, D.O.

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast …

18 years of age All Phase 2
C Claire Smith, MD

The COMPASSION Study

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

18 years of age All Phase N/A
A Agnes Flöel, Prof.

Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment

The aim of this study is to investigate whether a high definition tDCS-accompanied intensive cognitive training of working memory leads to performance improvement in women with post-chemotherapy cognitive impairment after breast cancer treatment.

18 - 65 years of age Female Phase N/A
I I-Chun Chen, M.D.,Ph.D

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

The 3 FDA-approved CDK4, 6 inhibitors, palbociclib, ribociclib, and abemciclib, all provided progression-free survival benefits when combined with endocrine therapy in advanced ER+/HER2- breast cancer. But, not all of them provided overall survival benefit in the same setting. One of the proposed mechanisms that influence the overall survival difference is …

20 years of age Female Phase 2
J Jue Wang, MD

Omission of SLNB in cN0 Early Breast Cancer

The OMSLNB trial adopts a prospective, single-arm, non-inferiority, phase-II, open-label study design. Patients with unilateral invasive breast cancer (tumor ≤3cm) and assessed as cN0 will be eligible for inclusion, enrolled patients are required to complete 2 or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and …

18 - 70 years of age Female Phase N/A

Simplify language using AI